[10] [22] Disease-modifying therapies commonly used in MS include: Injectable therapies : Interferon beta preparations (Avonex, Rebif, Betaseron) and glatiramer acetate (Copaxone) Oral agents : Fingolimod (Gilenya), dimethyl fumarate (Tecfidera), teriflunomide (Aubagio), siponimod (Mayzent), ozanimod (Zeposia), and cladribine (Mavenclad) Infusion therapies : Natalizumab (Tysabri), ocrelizumab (Ocrevus), alemtuzumab (Lemtrada) Subcutaneous injection : Ofatumumab (Kesimpta) No direct drug-drug interactions between tirzepatide and these DMTs have been identified in pharmacological studies
2001;131(3s):980S-984S
S.HaJ.BaekH
To confirm the presence of analytes in their charged states in solution, pH indicator probes and pre-charged analyte adducts of highly acidic ions from the solution can be used for detection
Efectos secundarios de Tirzepatida: Los efectos secundarios ms comunes de tirzepatida son de naturaleza gastrointestinal y suelen ser de leves a moderados, como: * Nuseas * Diarrea * Vmitos * Disminucin del apetito * Estreimiento * Malestar estomacal En general, tirzepatida se tolera bien, pero es importante hablar con un mdico sobre los posibles riesgos y beneficios antes de iniciar el tratamiento
When emotional eating triggers occur, individuals often turn to comfort foods, which are typically high in sugar and fat
